INO - Inovio Pharmaceuticals Stock Trading

Inovio Pharmaceuticals Inc.(NASDAQ: INO) stock trading, description, contact, officers and directors.

About Inovio Pharmaceuticals Inc.

The achievements of stimulating the immune system through vaccination have been profound. INO s synthetic vaccines are designed to treat as well as prevent illnesses, aiming to break the body s tolerance of cancerous cells and protect against diverse while changing strains of infectious diseases. INO s SynCon vaccines are designed to provide universal cross strain protection against known as well as newly emergent unmatched strains of pathogens such as influenza. These synthetic vaccines, in combination with Inovio s proprietary electroporation delivery, have been shown in humans to generate best in class immune responses with a favorable safety profile.

Stock Information

Inovio Pharmaceuticals Inc. Company Name:

INO Stock Symbol:

NASDAQ Market:

Inovio Pharmaceuticals Inc. Website:

INO - Inovio Pharmaceuticals Stock Trading

INO INO Quote INO Short INO News INO Articles INO Message Board

Get INO Alerts

News, Short Squeeze, Breakout and More Instantly...

INO - Nasdaq Shrugs Off Uncertainty as Piedmont Lithium Soars on Tesla Deal; Inovio Plunges on Clinical Halt

The Nasdaq Composite (NASDAQINDEX: ^IXIC) has gone through a correction over the past month, with investors facing an uncertain future. The COVID-19 pandemic, the U.S. presidential election, and issues like trade and economic stimulus are all making it difficult for market participa...
INO - Inovio Coronavirus Vaccine Candidate Trial Halted Due to FDA Inquiry

Inovio Pharmaceuticals (NASDAQ: INO) stock was really taking it on the chin Monday, following a very discouraging revelation from the company. The biotech announced that morning that the clinical trials for its INO-4800 COVID-19 vaccine candidate have been halted. This was becau...
INO - Why Inovio Stock Is Crashing Today

Shares of Inovio Pharmaceuticals (NASDAQ: INO) were crashing 32.5% lower as of 9:37 a.m. EDT on Monday. The huge decline came after the company announced that the U.S. Food and Drug Administration placed Inovio's filing to begin a phase 2/3 clinical study of COVID-19 vaccine candida...